U.S. Equity Strategy: Upgrading Health Care to Overweight
Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...
376 Views
Immunotech Biopharm (永泰生物) IPO: Challenges for Cellular Immunotherapies
Immunotech Biopharma, a leading cellular immunotherapy company in China, aims to raise USD 100 to 200 million via a Hong Kong listing. In this...
792 Views
Japan CAR-T Therapy Landscape
Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...
1.1k Views
Ascletis Pharma: Invalidation of Gilead Patents Won't Help
China's State Intellectual Property Office (SIPO) last week invalidated Gilead Sciences (GILD US) 's patent claims on the base compound for...
807 Views
Ascletis Pharma (1672 HK) IPO: First in Line
Ascletis Pharma is the first pharmaceutical company to file for an IPO in Hong Kong after the government allowed pre-revenue biotech companies to...
756 Views